Form 4 holding
Director
Atara Biotherapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 77,955
- Estimated value
- $589,339
- Report date
- 10 Jun 2025
- Price
- $7.56
- Ownership
- Direct
Pascal Touchon
Insider Reports History
- Reporting-owner location
- South San Francisco, CA
- Latest reporting-owner signature
-
/s/ John Chao, Attorney-in-Fact for Pascal Touchon
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Pascal Touchon
Form 4 holding
Director
Atara Biotherapeutics, Inc.
- Security class
- Employee Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 12 Aug 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Pascal Touchon
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 10 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2025, 20:39
- Role
- Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 Aug 2024
- Transactions
- 2
- Transaction value
- -$20,139
- Accepted by SEC
- 20 Aug 2024, 18:27
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 12 Aug 2024
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 14 Aug 2024, 18:00
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 May 2024
- Transactions
- 1
- Transaction value
- -$50,289
- Accepted by SEC
- 20 May 2024, 20:34
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 04 Mar 2024
- Transactions
- 1
- Transaction value
- -$17,888
- Accepted by SEC
- 06 Mar 2024, 18:19
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 08 Jan 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jan 2024, 16:41
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 Nov 2023
- Transactions
- 1
- Transaction value
- -$7,939
- Accepted by SEC
- 20 Nov 2023, 17:31
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 Aug 2023
- Transactions
- 2
- Transaction value
- -$50,835
- Accepted by SEC
- 18 Aug 2023, 18:25
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 27 Jun 2023
- Transactions
- 1
- Transaction value
- -$23,723
- Accepted by SEC
- 29 Jun 2023, 16:15
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 May 2023
- Transactions
- 1
- Transaction value
- -$60,633
- Accepted by SEC
- 18 May 2023, 20:17
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 02 Mar 2023
- Transactions
- 1
- Transaction value
- -$56,868
- Accepted by SEC
- 06 Mar 2023, 17:49
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 01 Mar 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Mar 2023, 16:16
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 Nov 2022
- Transactions
- 1
- Transaction value
- -$70,004
- Accepted by SEC
- 18 Nov 2022, 19:13
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 Aug 2022
- Transactions
- 1
- Transaction value
- -$74,548
- Accepted by SEC
- 18 Aug 2022, 18:24
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 27 Jun 2022
- Transactions
- 1
- Transaction value
- -$102,384
- Accepted by SEC
- 29 Jun 2022, 16:48
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 17 May 2022
- Transactions
- 1
- Transaction value
- -$73,962
- Accepted by SEC
- 19 May 2022, 17:04
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 01 Mar 2022
- Transactions
- 3
- Transaction value
- -$87,009
- Accepted by SEC
- 03 Mar 2022, 18:02
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 16 Nov 2021
- Transactions
- 1
- Transaction value
- -$143,816
- Accepted by SEC
- 18 Nov 2021, 16:55
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 17 Aug 2021
- Transactions
- 1
- Transaction value
- -$103,051
- Accepted by SEC
- 19 Aug 2021, 19:37
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 25 Jun 2021
- Transactions
- 1
- Transaction value
- -$231,660
- Accepted by SEC
- 29 Jun 2021, 16:06
- Role
- President and CEO, Director
- Next action
- Open filing details
4
ATRA
Atara Biotherapeutics, Inc.
- Report period
- 18 May 2021
- Transactions
- 1
- Transaction value
- -$120,954
- Accepted by SEC
- 20 May 2021, 16:31
- Role
- President and CEO, Director
- Next action
- Open filing details